Mesa Laboratories (MLAB) Director Reports 1,404 RSU Vesting and 2,784 RSUs Outstanding

Rhea-AI Filing Summary

Shannon Hall, a director of Mesa Laboratories, reported stock-based compensation transactions dated 08/15/2025. The filing shows 1,404 restricted stock units (RSUs) vested on that date and were converted into 1,404 shares of common stock with a reported acquisition price of $0. After the transaction Hall beneficially owns 4,189 shares directly. The filing also reports an additional grant of 2,784 RSUs that vest on 08/15/2026 and are recorded as 2,784 shares of underlying common stock. The Form 4 was executed under power of attorney and signed on 08/18/2025.

Positive

• Timely disclosure of insider transaction with filing executed shortly after the transaction date
• Vested RSUs converted to shares, increasing the reporting person's direct ownership to 4,189 shares
• No cash paid for the vested RSUs as reported (price = $0)
• Future RSUs disclosed with clear vesting date of 08/15/2026

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine RSU vesting increased a director's direct share count by 1,404 shares; no cash paid.

The transaction reflects standard equity compensation mechanics rather than a market-moving event. The vested RSUs converted to 1,404 shares at a reported price of $0, increasing Shannon Hall's direct holdings to 4,189 shares. An additional 2,784 RSUs remain scheduled to vest on 08/15/2026, representing future dilution when settled. For investors, this is a disclosure of insider alignment via equity compensation, but the absolute size is small relative to public-company float and does not indicate a change in company operations or financial condition.

Corporate Governance Expert

TL;DR: This is a standard director equity vesting disclosure; timing and POA signature are properly documented.

The Form 4 documents customary rollout of restricted stock units to a director with clear vesting dates and an executed filing under power of attorney. The filing shows no sale or cash purchase; vested units converted into shares and additional RSUs remain outstanding with a one-year vesting horizon. From a governance perspective the filing demonstrates routine director compensation and timely reporting, with no red flags such as accelerated dispositions or unexpected changes in control.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Shannon

(Last) (First) (Middle)

123 CLEARFIELD DRIVE

(Street)

SAN FRANCISCO CA 94132

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/15/2025		M		1,404	A	$0	4,189	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units - 7	(1)	08/15/2025		M			1,404	(2)	(3)	Common Stock	1,404	$0	0	D
Restricted Stock Units - 8	(1)	08/15/2025		A		2,784		(4)	(3)	Common Stock	2,784	$0	2,784	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of the Issuer's common stock

2. RSUs that vested on August 15, 2025

3. Not Applicable

4. RSUs that vest on August 15, 2026

	John Sakys under Power of Attorney by Shannon Hall	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Shannon Hall report on Form 4 for MLAB?

The Form 4 reports that 1,404 RSUs vested on 08/15/2025 and converted into 1,404 shares, increasing Hall's direct beneficial ownership to 4,189 shares.

Did Shannon Hall purchase shares on 08/15/2025 for MLAB?

No purchase price is reported; the vested RSUs were converted at a reported price of $0, indicating settlement from equity awards rather than a cash purchase.

Are there additional RSUs disclosed for Shannon Hall?

Yes, the filing shows 2,784 RSUs that are scheduled to vest on 08/15/2026 and correspond to 2,784 underlying shares.

What is the reporting person’s relationship to Mesa Laboratories (MLAB)?

Shannon Hall is reported as a Director of Mesa Laboratories, per the Form 4.

When was the Form 4 signed and who signed it?

The Form 4 was signed under power of attorney by John Sakys on 08/18/2025 on behalf of Shannon Hall.